Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORADUR-oxymorphone
- Development stage
- Unknown
- Lead developer
- Elite Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ORADUR-oxymorphone is a reformulated, oral, extended-release version of the semi-synthetic opioid analgesic oxymorphone that uses Durect’s ORADUR biodegradable depot/abuse-deterrent technology to provide controlled delivery of the active drug over an extended period for the management of moderate to severe chronic pain. Oxymorphone is a potent mu-opioid receptor agonist that alters pain perception and response in the central nervous system, with higher lipophilicity and rapid CNS penetration compared with morphine, while the ORADUR matrix is designed to resist common methods of tampering and to reduce abuse by crushing, snorting, or injection.[1][3][7]
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on ORADUR-oxymorphone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORADUR-oxymorphone.